Advantages of Phosphodiesterase Type 5 Inhibitors in the Management of Glucose Metabolism Disorders: A Clinical and Translational Issue

Among metabolic diseases, carbohydrate metabolism disorders are the most widespread. The most common glucose pathological conditions are acquired and may increase the risk of type 2 diabetes, obesity, heart diseases, stroke, and kidney insufficiency. Phosphodiesterase type 5 inhibitors (PDE5i) have...

Descripción completa

Detalles Bibliográficos
Autores principales: Antinozzi, Cristina, Sgrò, Paolo, Di Luigi, Luigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7407035/
https://www.ncbi.nlm.nih.gov/pubmed/32774364
http://dx.doi.org/10.1155/2020/7078108

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7407035/
https://www.ncbi.nlm.nih.gov/pubmed/32774364
http://dx.doi.org/10.1155/2020/7078108

Ejemplares similares